Sophion user publications: Q3 2025 ion channel breakthroughs
Another impressive collection of ion channel peer-reviewed publications from Sophion users in Q3 2025. This quarter’s publications cover a broad spectrum – from autoimmunity, pain, parasitic diseases, through to cardiac disease, safety and translation – emphasizing the diverse applications of automated patch clamp platforms.
This quarter, we highlight four particularly noteworthy studies showing how Sophion’s automated patch clamp platforms are accelerating our understanding of ion channels in physiology, pharmacology, and their translational potential.
- Novel Kv1.3 inhibitors with the potential to treat autoimmune diseases
In Abdelwaly et al., our first user publication from Africa, three Egyptian labs collaborated with Temple University, Philadelphia, to discover novel Kv1.3 inhibitors with the potential to treat autoimmune diseases. - Exploring Kv7 for oxylipins & lipoproteins pharmacology and long-QT loss-of-function mutant channels
Two Kv7 papers from the Swedish shared, core facility at Linköping University: Jonsson et al. explored oxylipins & lipoproteins pharmacology; whilst Hiniesto-Iñigo et al. used an endocannabinoid to rescue long-QT causing loss-of-function mutant channels. - hiPSC-cardiomyocytes for physiological translation of Nav1.5 modulator activity
Imredy et al. of Merck & Co. Inc., used hiPSC-cardiomyocytes for more physiologically relevant, accurate translation of Nav1.5 modulator activity in QRS prolongation.